[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"essential-primary-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:essential-primary-hypertension":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,85,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100648116","smartphone-guided-paced-breathing-and-aerobic-exercise-for-essential-hypertension-100648116",false,"NCT07717996","Smartphone-Guided Paced Breathing and Aerobic Exercise for Essential Hypertension","Effect of Smartphone-Guided Paced Breathing Combined With Aerobic Exercise on Blood Pressure, Functional Capacity, and Quality of Life in Patients With Essential Hypertension","SPB-HTN","Inclusion Criteria:\n\nAdults aged 40-50 years. Both males and females. Clinically diagnosed with essential (primary) hypertension confirmed by a physician.\n\nStage 1-2 hypertension (SBP 130-160 mmHg and\u002For DBP 80-100 mmHg) based on standardized clinical measurement.\n\nDuration of diagnosed hypertension between 6 months and 5 years. Stable on antihypertensive medication for at least 4 weeks prior to enrollment, with no planned medication changes.\n\nMedically stable and cleared for participation in moderate-intensity exercise. Able to understand instructions and independently perform smartphone-guided breathing exercises.\n\nWilling to participate and provide written informed consent.\n\nExclusion Criteria:\n\nSecondary hypertension (e.g., renal, endocrine, or medication-induced hypertension).\n\nSevere or uncontrolled hypertension (SBP \\>180 mmHg and\u002For DBP \\>110 mmHg). History of major cardiovascular events (e.g., myocardial infarction within the past 6 months, unstable angina, uncontrolled arrhythmias, or decompensated heart failure).\n\nChronic respiratory diseases affecting exercise tolerance (e.g., chronic obstructive pulmonary disease \\[COPD\\] or severe asthma).\n\nNeurological, musculoskeletal, or orthopedic conditions that limit safe participation in walking or exercise training.\n\nCognitive impairment or psychiatric disorders that affect comprehension or adherence to the study protocol.\n\nParticipation in a structured exercise or pulmonary rehabilitation program within the previous 3 months.\n\nHeavy smoking. Pregnancy or lactation. Contraindications to exercise testing or training according to the American College of Sports Medicine (ACSM) guidelines.\n\nAnticipated changes in antihypertensive medication during the study period.","ALL","40 Years","50 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25],"NA","Hypertension is a major risk factor for cardiovascular disease and is associated with reduced functional capacity and impaired quality of life. Non-pharmacological interventions, including aerobic exercise and paced breathing, may improve blood pressure control by enhancing cardiovascular and autonomic function. This randomized controlled trial will evaluate whether combining smartphone-guided paced breathing with aerobic exercise provides greater benefits than either intervention alone in adults with essential hypertension. Seventy-five participants will be randomly assigned to one of three groups: (1) smartphone-guided paced breathing combined with aerobic exercise, (2) aerobic exercise alone, or (3) smartphone-guided paced breathing alone. The intervention will last 12 weeks. The primary outcome measures are systolic and diastolic blood pressure. Secondary outcome measures include heart rate, functional capacity assessed by the 6-Minute Walk Test, and health-related quality of life assessed using the Short Form-12 (SF-12) questionnaire. The findings of this study may help identify an effective, accessible, and low-cost non-pharmacological strategy for improving cardiovascular health and quality of life in patients with essential hypertension.",[28],"Essential (Primary) Hypertension",[30,31,32,33,34,35,36,37,38,39,40,41],"Essential Hypertension","Aerobic Exercise","Smartphone-Guided Paced Breathing","Physical Therapy","Blood Pressure","Functional Capacity","Six-Minute Walk Test","Quality of Life","SF-12","Mobile Health","Nonpharmacological Treatment","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-07-21",{"date":45,"type":46},"2026-07-22","ACTUAL",{"date":48,"type":22},"2026-07-25",{"date":50,"type":22},"2026-12-01",{"name":52,"class":53},"Cairo University","OTHER",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100645112","evaluating-the-effects-of-a-mindfulness-intervention-on-health-outcomes-in-individuals-with-hypertension-100645112","NCT07679984","Evaluating the Effects of a Mindfulness Intervention on Health Outcomes in Individuals With Hypertension","Inclusion Criteria:\n\n1. Age \\>18 years old.\n2. Established patient at OSU Family Medicine\n3. Diagnosis of primary essential hypertension\n4. Ability and willingness to participate in all Mindfulness in Motion (MIM) study activities.\n5. Ability and willingness to download MyCap, the smartphone app that securely links participant study responses to the REDCap study project.\n6. WiFi connectivity or LTE to allow use of MIM smartphone app and MyCap when not at OSU clinical site.\n\nExclusion Criteria:\n\n1. Inability to read and\u002For understand English (MIM intervention, study consent and questionnaires in English).\n2. Established mindfulness practice.\n3. Diagnosis of secondary hypertension with identifiable underlying causes including:\n\n   * Chronic kidney disease\n   * Renal artery stenosis\n   * Primary aldosteronism\n   * Cushing's syndrome\n   * Pheochromocytoma\n   * Obstructive sleep apnea\n   * Medication induced hypertension (e.g., steroids, NSAIDs)\n   * Pregnancy related hypertension\n4. Current severe alcohol or substance abuse disorder.\n5. Participants with documented cognitive disorder that limits the ability to independently participate in MIM program, read, understand, and\u002For complete the surveys; i.e. dementia, Alzheimer's or biological tests.\n6. Participants with major psychiatric disorders not controlled by medication or other psychiatric treatments.","18 Years",{"count":62,"type":22},140,[25],"The purpose of this study is to evaluate the effectiveness of adding the Mindfulness in Motion (MIM) program to usual primary care for people with high blood pressure. MIM is a facilitated, 8-week online program that teaches simple ways to manage stress using mindfulness practices. The program also includes the use of a companion smartphone app throughout the 12-month study period. In this study, investigators will compare people who receive their usual care and take part in the MIM program with those who receive usual care alone to see if it helps improve blood pressure, weight, stress, sleep, and overall well-being. Over 12 months, participants will be asked to complete short questionnaires about stress, sleep, and resilience four times via a smartphone, tablet, or computer.",[66,28],"Hypertension",[68,69,70,71,72,73,74],"hypertension","primary care","mindfulness","stress","resilience","sleep","blood pressure","2026-07-01",{"date":77,"type":46},"2026-07-06",{"date":79,"type":22},"2026-10-01",{"date":81,"type":22},"2028-05-01",{"name":83,"class":53},"Ohio State University",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100640759","phase-4-effect-of-the-traditional-chinese-medicine-yufeng-ningxin-in-patients-with-hypertension-100640759","NCT07607275","Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension","Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Male and female participants aged 18-65 years;\n2. Newly diagnosed, untreated hypertension or treated hypertension with a seated systolic blood pressure of 140-159 mmHg and a daytime mean ambulatory systolic blood pressure ≥135 mmHg, following a ≥2-week washout of background antihypertensive medications;\n3. The patient is capable of understanding the study requirements, is willing and able to comply with study procedures, and has provided written informed consent.\n\nExclusion Criteria:\n\n1. Secondary hypertension (including, but not limited to, renovascular hypertension, pheochromocytoma, primary aldosteronism, Cushing syndrome, aortic coarctation, or due to known history of moderate-to-severe obstructive sleep apnea);\n2. Orthostatic hypotension (symptomatic or asymptomatic);\n3. Participation in another hypertension-related clinical trial at enrollment or within 6 months prior;\n4. Currently taking, taken within 30 days prior to randomization, or anticipated to receive during the study treatment period any medication or herbal supplement known to significantly affect blood pressure (with the exception of medications for the treatment of essential hypertension). These drugs include, but are not limited to: organic nitrates, glucocorticoids (excluding topical or inhaled corticosteroids), central nervous system stimulants (e.g., methylphenidate, dexmethylphenidate, amphetamines), estrogens, monoamine oxidase inhibitors, digitalis preparations, Chinese proprietary medicines (such as Tianma Gouteng Granules, Songling Xuemaikang Capsules, Yangxue Qingnao Granules), and herbal medicines (including Salvia miltiorrhiza, Uncaria rhynchophylla, Ginkgo biloba leaves, Prunella vulgaris, etc.);\n5. Users of prescription non-steroidal anti-inflammatory drugs (NSAIDs); initiation of, changes to, or discontinuation of sodium-glucose co-transporter (SGLT2) inhibitor therapy within 4 weeks prior to screening. Patients who were stably taking an SGLT2 inhibitor or low-dose aspirin (defined as ≤100mg per day) for at least 4 weeks prior to screening with no anticipated changes during the study are permitted;\n6. Severe hepatic or renal diseases (ALT \\>3 times the upper limit of normal value, or end stage renal disease on dialysis, or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2);\n7. Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c\\>9.0%);\n8. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack \\[TIA\\]);\n9. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months;\n10. Sustained atrial fibrillation or arrhythmias interfering with electronic BP measurement;\n11. NYHA class III-IV heart failure, or hospitalization for chronic heart failure exacerbation within the past 6 months;\n12. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period;\n13. Dilated cardiomyopathy, hypertrophic cardiomyopathy, rheumatic heart disease, or congenital heart disease;\n14. Other severe diseases that may affect participant enrollment or survival, such as malignancy or acquired immunodeficiency syndrome (AIDS);\n15. Cognitive impairment or severe neuropsychiatric comorbidities that render the patient incapable of providing informed consent;\n16. Participants preparing for or under pregnancy and\u002For lactation;\n17. Frequent night-shift work, with primary working hours during nighttime (e.g., 8:00 PM to 8:00 AM);\n18. Other conditions deemed inappropriate for participation by the investigators.","65 Years",{"count":94,"type":22},350,[96],"PHASE4","Yufeng Ningxin, a traditional Chinese medicine, has demonstrated potential antihypertensive effects in animal studies and small clinical trials, but has not yet been rigorously evaluated in large randomized clinical trials. Here, the investigators conducted a double-blind, randomized controlled trial to assess the efficacy and safety of Yufeng Ningxin tablets in patients with hypertension.",[66,28],"RECRUITING","2026-05-29",{"date":102,"type":46},"2026-06-02",{"date":104,"type":22},"2026-05-15",{"date":106,"type":22},"2028-06-01",{"name":108,"class":53},"Beijing Anzhen Hospital",16,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":130,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":84},"100622407","effect-of-electrical-stimulation-and-exercise-on-blood-flow-in-patients-with-resistant-high-blood-pressure-100622407","NCT07383220","Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure","Effect of Combined Transcutaneous Electrical Stimulation and Isometric Exercise on Peripheral Hemodynamic Parameters in Patients With Resistant Hypertension","Inclusion Criteria:\n\n* Age between 50 and 60 years. Both sexes were included Patients had been diagnosed with hypertension for at least 5 years.\n\nPatients had resistant hypertension according to (Whelton et al 2018), defined as:\n\n* Systolic blood pressure (SBP) ≥140 mmHg and\u002For diastolic blood pressure (DBP) ≥90 mmHg despite the use of three or more antihypertensive medications of different classes, including a diuretic,\n* or controlled blood pressure (\\\u003C140\u002F90 mmHg) while on four or more antihypertensive medications.\n\nBody Mass Index (BMI) 25: 34.9 kg\u002Fm²\n\nIncreased waist circumference, defined as:\n\n* Greater than 102 cm for males.\n* Greater than 88 cm for females.\n\nExclusion Criteria:\n\n* Secondary hypertension due to identifiable causes (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma).\n* History of major cardiovascular events in the last 6 months (e.g., myocardial infarction, stroke, or heart failure exacerbation).\n* Severe musculoskeletal or neurological disorders that impair the ability to perform isometric exercise safely (e.g., recent joint replacement, severe osteoarthritis, stroke with residual motor deficit).\n* Contraindications to the use of Transcutaneous Electrical Nerve Stimulation (TENS):\n\nImplanted electronic devices: pacemakers, cardioverter defibrillators. Uncontrolled arrhythmias. Sever skin condition: open wounds, rashes, burns, eczema. Peripheral neuropathy or sensory loss.\n\n-Known cognitive impairment or psychiatric conditions that would limit the ability to follow instructions or provide informed consent.","60 Years",{"count":119,"type":22},50,[25],"The goal of this clinical trial is to learn if the combination between transcutaneous electrical nerve stimulation (TENS) and isometric exercise (IE) can improve blood pressure in men and women between 50 to 60 years old suffered from resistant hypertension which is a type of hypertension where blood pressure remains above your target goal despite the use of three or more different classes of antihypertensive medications at their maximum tolerated doses. The main question to answer is:\n\nIs there a significant effect on the combined use of TENS and IE on peripheral hemodynamic parameters in patients with resistant hypertension? Total sample will be 50 patients from both sexes\n\nI will compare between two groups:\n\nExperimental group (15 men, 10 women) will take: medication plus IE and TENS Control group (15 men, 10 women) will take: medication plus Conventional Physical Therapy Program",[123,124,28,125,126,127,128,129],"Resistant Hypertension","Hemodynamic Instability","Abdominal Obesity","Metabolic Syndrome","Hypertension (HTN)","Vascular Resistance","High Blood Pressure",[131,132,33,133,134,135,136,137],"Mean Arterial Pressure","Peripheral Hemodynamics","Long Term Hypertension","Resistant HTN","Systolic Blood Pressure (SBP)","Diastolic Blood Pressure (DBP)","Heart Rate Variability (HRV)","2026-01-28",{"date":140,"type":46},"2026-02-03",{"date":142,"type":22},"2026-01-15",{"date":144,"type":22},"2026-06-10",{"name":146,"class":53},"Mohamed Mohamed Ali Morgan"]